Bio-Techne TECH Business Segments
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Diagnostics And Spatial Biology | $85.59M-4.1% | $81.18M-3.5% | $79.46M-4.5% | $89.71M-1.1% | $89.23M+2.0% | |
| Protein Sciences | $226.15M-0.7% | $215.08M+1.7% | $202.19M-1.1% | $226.47M+5.8% | $227.69M+6.1% | |
| Revenue by Product | ||||||
| Consumables | $257.34M-0.2% | $235.44M+2.0% | $231.6M+0.3% | $252.94M+2.9% | $257.79M+4.5% | |
| Instruments | $27.66M+5.9% | $29.61M-4.1% | $21.83M-16.7% | $28.9M+6.7% | $26.11M-1.4% | |
| Royalty | $4.97M-1.4% | $8.51M+5.1% | $5.65M+11.8% | $5.51M+9.0% | $5.04M+7.2% | |
| Service | $21.45M-21.3% | $22.32M-18.4% | $27.48M+0.5% | $29.62M+5.1% | $27.25M+6.8% | |
| Revenue by Geography | ||||||
| APAC Excluding Greater China | $21.82M+2.7% | $22.74M+19.6% | $19.15M+5.7% | $18.89M-1.9% | $21.25M+16.4% | |
| CN | $26.01M+6.2% | $26.35M+6.5% | $24.79M+1.9% | $26.91M+12.5% | $24.48M-4.4% | |
| EMEA Excluding UK | $73.45M+10.4% | $75.35M+7.0% | $65.13M+10.3% | $70.35M+10.7% | $66.5M+9.9% | |
| GB | $14.89M+15.9% | $13.73M+3.7% | $13.21M-5.3% | $14.79M+25.7% | $12.85M-15.0% | |
| Rest Of World | $7.77M-15.4% | $11.15M+14.6% | $9.05M+0.6% | $9.65M-4.0% | $9.18M-13.5% | |
| US | $167.48M-7.9% | $146.56M-8.3% | $155.24M-5.9% | $176.39M-0.6% | $181.92M+5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Techne break its business down?
- Bio-Techne (TECH) reports revenue by business across 2 parts — Diagnostics And Spatial Biology and Protein Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Techne's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Techne's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
